News

Wane1mon
SystImmune, Inc. to Present Updated izalontamab brengitecan (iza-bren) Data in Locally Advanced or Metastatic Breast Cancer at ESMO Breast 2025 - WANE 15
- Updated safety & efficacy in Locally Advanced or Metastatic Breast Cancer will be presented from a Ph1 clinical study evaluating iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based ...
WHNT1mon
SystImmune, Inc. to Present New izalontamab brengitecan (iza-bren) Data in Small Cell Lung Cancer and Non-Small Cell Lung Cancer with Driver Genomic Alterations (GA) outside of ...
REDMOND, Wash., May 23, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts on izalontamab brengitecan (iza-bren), a ...
The Victoria Advocate6mon
SystImmune, Inc. to Present Updated BL-B01D1 Data in Breast Cancer at SABCS Congress 2024
- Updated safety & efficacy data in locally advanced or metastatic breast cancer patients will be presented from a phase 1 clinical study evaluating BL-B01D1, an EGFRxHER3 bispecific topoisomerase ...
NBC4 Columbus1mon
SystImmune, Inc. to Present New izalontamab brengitecan (iza-bren) Data in Small Cell Lung Cancer and Non-Small Cell Lung Cancer with Driver Genomic Alterations ... - NBC4 WCMH-TV
REDMOND, Wash., May 23, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts on izalontamab brengitecan (iza-bren), a ...
NBC4 Columbus1mon
SystImmune, Inc. to Present Updated izalontamab brengitecan (iza-bren) Data in Locally Advanced or Metastatic Breast Cancer at ESMO Breast 2025 - NBC4 WCMH-TV
- Updated safety & efficacy in Locally Advanced or Metastatic Breast Cancer will be presented from a Ph1 clinical study evaluating iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based ...